This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01511/identifier/bindingdb/
foafhttp://xmlns.com/foaf/0.1/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01511/identifier/pubchem-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01511/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01511/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01511/identifier/drugbank/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n13http://linked.opendata.cz/resource/drugbank/drug/DB01511/identifier/chemspider/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://www.drugs.com/international/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01511/identifier/wikipedia/

Statements

Subject Item
n2:DB01511
rdf:type
n3:Drug
n3:description
Delorazepam is a benzodiazepine which, like other drugs in its class, possesses anxiolytic, skeletal muscle relaxant, hypnotic and anticonvulsant properties. It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. [4] Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. It is a long acting benzodiazepine which makes it superior in this sense to lorazepam which is short acting. Lorazepam is also a major active metabolite of delorazepam. In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. [Wikipedia] It has been approved for marketing in Italy.
n3:generalReferences
1. Bareggi, S. R., et al. "Age-related multiple-dose pharmacokinetics and anxiolytic effects of delorazepam (chlordesmethyldiazepam)." International journal of clinical pharmacology research 6.4 (1986): 309. 2. Bareggi, S. R., et al. "Effects of liver disease on the pharmacokinetics of intravenous and oral chlordesmethyldiazepam." European journal of clinical pharmacology 48.3-4 (1995): 265-268. 3. Cazzato, G., et al. "[Prevention and therapy of delirium tremens with tiapride and chlordesmethyldiazepam]." Rivista di neurologia 52.6 (1981): 331-342. 4. Scarone, S., L. F. Strambi, and C. L. Cazzullo. "Effects of two dosages of chlordesmethyldiazepam on mnestic-information processes in normal subjects." Clinical therapeutics 4.3 (1981): 184. 5. Sennesael, J., et al. "Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis." European journal of clinical pharmacology 41.1 (1991): 65-68.
n3:group
illicit experimental approved
n3:halfLife
Very long elimination half life of 80-115 hours, varying with age. Elimination is slower as age increases. [1] Liver disease also impacts elimination half life, with impairment resulting in half lives up to 395 hours. [2]
n3:indication
Mainly used as an anti-anxiety agent. Studies have found delorazepam to be more effective in the first 4 weeks of use than antidepressants; however, after 4 weeks, antidepressants showed superior anti-anxiety effects. [Wikipedia] Anti-anxiety effects also appear to be weaker in elderly patients. [1] Effectiveness has also been observed in the treatment of alcohol withdrawal. Delorazapam was reported to be a manageable drug in that it did not exhibit severe side effects and did not require further therapies to control symptoms of withdrawal. [3]
owl:sameAs
n6:DB01511 n14:DB01511
dcterms:title
Delorazepam
adms:identifier
n9:D07784 n10:Delorazepam n13:16929 n15:DB01511 n16:50026858 n17:17925 n18:46504957
n3:routeOfElimination
Renally eliminated.
n3:synonym
Dadumir Chlordesmethyldiazepam CDDZ
n3:toxicity
Older patients metabolize delorazepam slower than younger patients and thus suffer from more adverse effects. [1]
n3:volumeOfDistribution
140 L/kg apparent volume of distribution in 11 patients with normal renal function; 47 L/kg in 11 patients with renal failure and on regular hemodialysis. [5] In another study, apparent volume of distribution was 65 L/kg in 8 patients with liver disease and 118.4 L/kg in 12 healthy controls. [2]
n3:proteinBinding
>90% protein bound. [5]
foaf:page
n12:delorazepam.html
n3:IUPAC-Name
n4:271B5101-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5107-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5106-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5103-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5104-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5105-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B50FF-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5100-363D-11E5-9242-09173F13E4C5 n4:271B50FD-363D-11E5-9242-09173F13E4C5 n4:271B5117-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B50FE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B510D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B510E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5108-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5109-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B510B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B510A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B510C-363D-11E5-9242-09173F13E4C5
n3:absorption
77-87% oral bioavailability, with a relatively slow absorption rate. [5] Reaches peak plasma levels within 1-2 hours of administration. Food may slow absorption, however other pharmacokinetic variables remain unchanged. After multiple doses delorazepam accumulates, however accumulation is slower in younger patients.[1]
n3:casRegistryNumber
2894-67-9
n3:category
n3:clearance
Still detectable 72 hours after dosing in healthy patients. Patients with liver disease experienced a reduction in clearance from 0.13 to 0.25 ng/mLh. [2]
n3:Bioavailability
n4:271B5113-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5115-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5116-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5112-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5111-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5114-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5102-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B510F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5110-363D-11E5-9242-09173F13E4C5